Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) Uses, Dosage, Side Effects, Food Interaction and all others data.

The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection. It also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2. These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants.

Trade Name	Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
Generic	Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Innovators Monograph

You find simplified version here Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)